Skip to main content
Terug
Watch Compare

Yubo International Biotech Ltd

Datakwaliteit: 100%
YBGJ
OTC Manufacturing Measuring & Analyzing Instruments
€ 0,01
€ 0,00 (0,00%)
Marktkapitalisatie: 1,62 M
Prijs
€ 0,01
Marktkapitalisatie
1,62 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -842.802,0

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)255,99%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net Margin-8736,73%
Op. Margin-9614,64%

Veiligheid

Debt / Equity
N/A
Current Ratio0,25
Interest CoverageN/A

Waardering

PE (TTM)
-1,50
Onder sectorgemiddelde (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -1,5 -1,5
P/B — 1,6
ROE % — -54,5
Net Margin % -8736,7 -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

All Fundamental Metrics
Growth
Revenue Growth (1Y) 255,99% Revenue Growth (3Y) -85,71%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 12.353,0 Net Income (TTM) -1,08 M
ROE N/A ROA -107,67%
Gross Margin 66,10% Operating Margin -9614,64%
Net Margin -8736,73% Free Cash Flow (TTM) -842.802,0
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,25
Interest Coverage N/A Asset Turnover 0,01
Working Capital -1,91 M Tangible Book Value -1,71 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,50 Forward P/E N/A
P/B Ratio N/A P/S Ratio 131,06
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -52,06%
Market Cap 1,62 M Enterprise Value 1,61 M
Per Share
EPS (Diluted TTM) -0,01 Revenue / Share 0,00
FCF / Share 0,00 OCF / Share 0,00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 78,09%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 12.353,0 3.470,0 604.676,0 104.283,0 —
Net Income -1,08 M -1,98 M -1,20 M -1,20 M -1,54 M
EPS (Diluted) -0,01 -0,02 — — —
Gross Profit 8.165,0 2.648,0 419.185,0 52.652,0 820.647,0
Operating Income -1,19 M -1,77 M -1,19 M -1,21 M -1,54 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses — — — — —
D&A 167.581,0 169.875,0 178.312,0 18.098,0 21.401,0
Interest Expense — 50,0 -377,0 229,0 427,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 847.094,0 1,53 M 1,67 M 2,35 M 4,59 M
Total Liabilities 2,79 M 4,83 M 3,51 M 2,91 M 4,72 M
Shareholders' Equity -1,95 M -3,42 M -1,84 M -565.373,0 -131.198,0
Total Debt — — — — —
Cash & Equivalents 8.062,0 7.015,0 6.359,0 18.220,0 27.517,0
Current Assets 667.512,0 682.751,0 725.235,0 750.012,0 1,06 M
Current Liabilities 2,79 M 4,72 M 3,40 M 2,52 M 2,79 M